` WBIO (WPD Pharmaceuticals Inc) vs S&P TSX Composite Index (Canada) Comparison - Alpha Spread

WBIO
vs
S&P TSX Composite Index (Canada)

Over the past 12 months, WBIO has significantly outperformed S&P TSX Composite Index (Canada), delivering a return of 367% compared to the S&P TSX Composite Index (Canada)'s 20% growth.

Stocks Performance
WBIO vs S&P TSX Composite Index (Canada)

Loading
WBIO
S&P TSX Composite Index (Canada)
Add Stock
www.alphaspread.com

Performance Gap
WBIO vs S&P TSX Composite Index (Canada)

Loading

Over the past 12 months, WBIO has outperformed S&P TSX Composite Index (Canada) by 346.97%.

WBIO
S&P TSX Composite Index (Canada)
Difference
www.alphaspread.com

Performance By Year
WBIO vs S&P TSX Composite Index (Canada)

Loading
WBIO
S&P TSX Composite Index (Canada)
Add Stock

Competitors Performance
WPD Pharmaceuticals Inc vs Peers

S&P TSX Composite Index (Canada)
WBIO
6362
PH
ATCO A
7011
Add Stock

WPD Pharmaceuticals Inc
Glance View

Market Cap
324.8k CAD
Industry
Machinery

WPD Pharmaceuticals, Inc. is biotechnology research and development company. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2008-05-26. The firm focuses on oncology, research and development of medicinal products involving biological compounds and small molecules. The firm has approximately nine drug candidates with four that are in clinical development stage and five in pre-clinical development. The Company’s drug development focuses on melanoma, brain cancer, leukemia and pancreatic cancer. Its portfolio for brain cancer includes WPD101, Berubicin and WP1066. Its portfolio for pancreatic cancer includes WP1066. Its portfolio for melanoma includes WP1066. Its portfolio for other cancers includes WPD103, WP1220 and Annamycin.

WBIO Intrinsic Value
0.001 CAD
Overvaluation 98%
Intrinsic Value
Price
W
Back to Top